Pharmaceuticals company Ajanta Pharma announced Q1FY26 results Revenue from operations at Rs 1,303 crore. against Rs 1,145 crore; up 14%. EBITDA at Rs 351 crore. against Rs 330 crore, up 6%; EBITDA at 27%. Profit after tax at Rs 255 crore. against Rs 246 crore; up 4%; PAT at 20%. The mark-to-market forex loss stood at Rs 25 crore. Excluding this impact, EBITDA stood at Rs 376 crore, reflecting a 14% growth, with an EBITDA margin of 29%. PAT grew by 12%, with a PAT margin of 21%. Cashflow from operations (CFO) was Rs 282 crore, EBITDA to CFO conversion of 80%. Free cashflow (FCF) was Rs 209 crore, FCF to PAT conversion of 82%. ROCE stood at a healthy level of 33% and RONW at 26%. Result PDF